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ABSTRACT 
Blood Bank Practices for Sickle Cell Patients in North Carolina 
ArabaN. Afenyi-Annan 
Sickle cell disease (SCD) remains an important public health problem. 
Predominantly affecting African Americans, SCD is associated with significant 
health, financial, and psychosocial costs. Therefore, it is vital to find new ways to 
improve delivery of care to this patient population. 
The hospital blood bank plays a key role in delivering transfusion therapy to SCD I 
' 
patients. Because transfusion therapy represents the mainstay of treatment for 
most SCD patients, we hypothesized that a systematic review of blood bank 
practices for these patients might uncover new opportunities to improve this care. 
Current blood bank practices for SCD patient have not been previously described. 
This paper discusses blood bank practices for SCD patients in North Carolina. 
The layout is as follows. First, the underlying cause, history, and costs of sickle 
cell disease are described. Next, evidence supporting the use of transfusions for 
SCD management and its associated risks are considered. Data from a cross-
sectional study ofNC blood bank practices for SCD patients are then presented. 
Finally, the significance and implications of this research are discussed. 
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INTRODUCTION 
Sickle cell disease (SCD) is a heterogeneous group of inherited disorders, 
characterized by the vasa-occlusive episodes with end organ damage, chronic 
pain and hemolytic anemia*. Replacement of a single amino acid (i.e. point 
mutation) in both ~-subunits of the hemoglobin (Hgb) molecule causes a 
conformational change of red blood cells (RBCs) under low oxygen tension, 
resulting in the characteristic "sickle cells" observed microscopically in a 
peripheral blood smear for which this disease is named. Clinically, SCD varies in 
severity both within and between specific genotypes; however, all SCD patients 
have abnormal RBCs that 1) are poor carriers of oxygen, 2) break easily creating 
a state of chronic anemia, and 3) lodge in small caliber vessels further preventing 
oxygen delivery to the tissue. 
Approximately 70,000 to 80,000 Americans have SCD making this one of 
the most common genetic disorders; an additional2.5 million carry the sickle cell 
trait. 1' 2 Although SCD occurs in a variety of racial/ethnic groups, this disease 
disproportionately affects African Americans, an already vulnerable population. 
In the United States, health disparities clearly exist for patients in racial/ethnic 
minorities and those with lower educational attainment and socio-economic 
status. SCD patients typically fall into all of these categories? An important 
national goal is the reduction and elimination of these health disparities.4 
More than thirty years ago, SCD was formally recognized as a national 
health priority.2 In 1972, the National Sickle Cell Anemia Control Act was 
signed into law providing for the establishment of screening and counseling 
programs, health education for both health providers and the public, and finally, 
research and research training. Shortly thereafter, the Secretary of Department of 
Health and Human Services (formerly known as the Department of Health, 
Education, and Welfare) created a National Sickle Cell Disease Program under 
the direction of the National Heart Lung and Blood Institute (NHLBI) within the 
National Institutes of Health (NIH)*. Since then, NHLBI has devoted over 923 
million dollars for research in SCD.2 Through the Blood Diseases Program, under 
the Division of Blood Diseases and Resources, NHLBI develops and disseminates 
materials on SCD, supports research on the use of blood and blood components in 
the treatment and prevention of disease, and leads a national multidisciplinary 
program of basic, clinical and applied research through NIH funded 
Comprehensive Sickle Cell Centers.5 Although these efforts have dramatically 
improved the lives of SCD patients, this chronic disease still remains an important 
public health issue today. 
In addition to disease morbidity and mortality, there are significant 
societal and individual costs for persons affected with SCD. Annual total health 
care costs for SCD patients exceed $3 billion dollars6 due to frequent interactions 
with the health care system. Inpatient admissions occur at a rate of 0.9 per patient 
per year (75,000 hospitalizations armually) with an estimated cost in excess of 
4 7 5 million dollars? Outpatient visits occur at a rate of 8 visits per patient per 
year. 8 Total hospital and physician charges are estimated to be in the order of 
$8,000 dollars per patient per year. 8 Nearly all SCD patients rely on government 
support through national and state programs to pay for these high medical 
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expenditures.9' 11 Individual costs include financial strain, mood disorders such as 
anxiety and depression, drug abuse, developmental delays, frequent interruptions 
in school and work, and inability to work secondary to chronic disability. All of 
these factors present a tremendous burden to patients, their families, and society. 
In addition to these costs, SCD patients remain at risk for early mortality and 
significant disease morbidity. 
Once a uniformly fatal disease of childhood, today> 85% of children with 
SCD survive past 18 years of age.2• 12 This contrasts with 1974 autopsy data that 
showed the average life span of a person with SCD in the United States was 
approximately 14 years. 13• 14 Today, the average life expectancy for African 
American males affected by SCD is 42 years and 45 years for affected African 
American females. 15 Although sickle cell patients now live into late adulthood, 
their life expectancy is still decreased by approximately 25 to 30 years as 
compared to their African American counterparts in the United States. Risk 
factors for early mortality include frequent pain episodes, renal failure, stroke, and 
acute chest syndrome, all of which represent significant disease morbidity. 16 
Disease morbidity is secondary to the chronic occlusion of vessels causing 
painful "crisis" and end organ damage as described above. Commonly affected 
organs include the spleen, brain, lungs, kidney, and joints. Complications in 
SCD patients include painful crisis, aplastic anemia, acute chest syndrome, stroke, 
and renal failure. Surgical complications, even for minor surgeries such as 
tonsillectomy and cholecystectomy, occur in up to 35% ofpatients.17' 18 These 
complications are potentially life threatening. 
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An important advancement in the management of this disease has been use 
of transfusion therapy, which has been a key component of improved survival 
rates in SCD patients.19 For the great majority of SCD patients, transfusion 
therapy represents the mainstay of care. By age 20, approximately 70-80% of 
patients will have been transfused. 18• 20.23 The underlying rationale for using RBC 
transfusions is to improve tissue oxygenation by decreasing the proportion ofHbS 
red cells and suppressing further production ofHbS through replacement of sickle 
cells with blood from normal donors. 
The benefits of transfusion therapy, which include decreased morbidity 
and mortality, have been demonstrated in a few randomized control trials (RCT) 
and several observational studies. The first RCT to demonstrate a dramatic I 
J reduction in disease morbidity and mortality with the use of transfusions was a 
1998 study comparing the incidence of stroke among children with SCD 
identified as high risk by transcranial Doppler ultrasound. The authors of this 
study found a greater than 90% reduction in the incidence of first stroke in 
children who received periodic prophylactic transfusions (chronic transfusions).24 
This trial was stopped after only 18 months due to overwhelming morbidity for 
patients in the non-transfusion arm. Other studies have shown that chronic 
transfusions also reduce the risk of recurrent stroke in children.Z5• 26 Studies in 
both children and adult patients receiving chronic transfusions have shown a 
reduction in hospitalization rates, emergency room visits, recurrence of acute 
chest syndrome, and severity and frequency of severe pain episodes.27.30 A RCT 
comparing the use of aggressive vs. conservative transfusions in SCD patients 
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undergoing surgery showed a decrease of some peri-operative complications.18 
Based on these and other studies, transfusion are recommended for the acute 
management oflife threatening and organ threatening vaso-occlusive episodes 
such as acute chest syndrome, multi-system organ failure, splenic sequestration, 
and stroke and prevention of disease complications?6•31 .35 
Transfusion therapy however, is not without risks. Potential 
complications of transfusion therapy, as for any patient, include transmission of 
infectious diseases, allergic reactions, and hemolytic and non-hemolytic 
transfusion reactions. Sickle cell patients however, are at increased risk for 
hyperviscosity, iron overload, painful episodes, alloimmunization, and severe 
hemolytic transfusion reactions (delayed and acute )_36-38 
Alloimmunization is the most frequent and problematic complication of 
transfusion therapy. Rates of alloimunization for SCD patients in the published 
literature vary from 18 to 36%?1• 22 ' 39-41 These are significantly higher than those 
in other chronically transfused populations such patients with ~-thalessemia 
(5%).41 -44 On average, 1/3 of SCD patients who receive transfusions develop 
alloantibodies to RBC antigens that are not present on their own RBCs. Figure 1 
illustrates the mechanism by which alloimmunization occurs. The risk of 
alloimmunization also increases with each transfusion episode.40 The mean 
number of units a chronically transfusion SCD patient receives is approximately 
30 units/year (range= 17-42 units/year).45 The consequences of alloimunization 
include difficulty obtaining compatible blood for transfusions. In the past 2 
decades, SCD patients have been the single largest users of national rare donor 
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blood*.46 
Differences in antigen frequencies between blood donors and SCD 
patients, particularly of the Rh and Kell blood groups, are thought to constitute a 
major reason for the high rates of alloimmunization observed in this population.22• 
40
•
47 Because the frequency of red cell antigens vary by racial/ethnic groups, the 
probability of transfusing a SCD patient with blood of a similar antigen profile is 
several times greater if blood from an African American donor is used. The 
probability of finding a compatible unit of blood is dependent upon the number of 
antigens required to be absent on donor red cells and the demographic 
composition of the donor pool. For example, the probability of finding a 
compatible unit lacking the three most common antigens missing on the red cells 
of African Americans (C, E, and K) is 1/33 in the typical donor pool composed of 
90% Caucasians and < I 0% African American. In contrast, finding these same 
units screening only African American donors is 114, an 8 fold difference.48 More 
recently, Castro et a!. showed that one is 24 times more likely to find a compatible 
unit lacking nine of the most common antigens causing alloimmunization in SCD 
patients if blood is selected from an African American donor.49 However, the 
small number of African American blood donors relative to the entire donor 
pool. 5°· 51 52 makes this approach impractical. Prophylactic antigen matching, that 
is providing SCD patients with blood from donors who lack similar major and l 
minor red cell antigens before antibody development, is an alternate strategy to 
decrease alloimmunization rates and prevent associated hemolytic transfusion 
reactions. 
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Hemolytic transfusion reactions in SCD patients range from mild to life 
threatening. Delayed hemolytic transfusion reactions occur days to weeks after 
being transfused with red cells containing antigens absent on their own red cells. 
Although usually mild, these reactions can severe and also precipitate more 
serious SCD related complications. 32' 53 ' 54 Life threatening reactions include 
acute transfusions reactions. One atypical reaction that occurs in SCD patients is 
the "hyperhemolysis phenomenon" where the patient destroys transfused donor 
red cells as well their own red cells.55' 56 This cycle of destruction is potentially 
fatal. 
Alternatives to transfusion therapy include medication (hydroxyurea) to 
decrease the frequency of disease related complications57 and bone marrow 
transplantation for potential cure. 58 Most patients however will still rely on 
transfusion therapy for treatment. Therefore, managing the risks of transfusion 
therapy by judicious use of transfusions in clinical practice and identifying new 
opportunities to improve delivery of this therapy remain critically important to 
improving the health of this patient population. 
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BACKGROUND 
North Carolina (NC) is "a national model for innovation and excellence in 
the diagnosis, treatment, and research ofSCD".59 This is due in part to two 
important factors, the large number of persons affected by SCD in the state and its 
longstanding comprehensive state sickle cell program. African Americans 
comprise 22% of the NC's population.60 Of the 1.7 million African Americans in 
North Carolina, about one out of every 294 is born with SCD and approximately 
12,730 newborns carry sickle cell trait.61 About 2400 children and adults have 
been diagnosed with SCD; an estimated 500 remain unidentified. 59 The North 
Carolina Sickle Cell Program (NCSCP) was one of the first state programs in the 
country.59 Created in 1973 in the Department of Health and Human Services, 
Division of Maternal and Child Health, it serves to promote the health and well 
being of persons with SCD through the reduction of mortality and morbidity. It 
accomplishes this mission through free newborn screening, genetic counseling to 
those with sickle trait, education to health professionals and the public, financial 
assistance for medical services, and coordinated care through a multidisciplinary 
program of four (4) community based centers and six (6) academic and regional 
medical centers in the state. 59•61 The latter includes a NIH-funded 
Comprehensive Sickle Cell center shared between two large academic centers, 
Duke University and The University of North Carolina. Studies suggest that SCD 
patients receive better quality of care through comprehensive sickle cell centers.12' 
62,63 
One aspect of care that has not been the focus of much attention is the 
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practices of blood bank as a component of the delivery of transfusion therapy. 
Specifically, blood banks provide laboratory testing of patient samples, special 
transfusion services, blood products for transfusion, and clinical oversight for the 
management of transfusion complications. Despite these functions, blood bank 
practices for SCD patients have not been well studied. To date, there have been 
no studies that provide a comprehensive overview ofthe way blood banks are 
currently managing SCD patients. 
Two important sources for transfusion management guidelines for SCD 
patients are the updated Nlli monograph "The Management of Sickle Cell 
Disease"14 and a consensus document from an international workshop of 
hematologists held in 1999, published in Seminars in Hematology. 64 Both 
describe the appropriate indications for transfusions, blood product use and 
administration techniques, and the diagnosis and management of transfusion 
related complications. Despite the existence of these sources, some aspects of 
managing SCD patients remain unclear. 
One example of this is the use of antigen matched RBCs for all SCD 
patients. Several authors have promoted the widespread use of this practice; 
others support its use in a more limited fashion. 38• 39• 47• 65 Recent studies 
describing the use of antigen matched RBCs for SCD patients among blood banks 
confirmed that no single standard of care exists for this practice. 66• 67 
Based on review of the literature, anecdotal evidence, referral patterns, and 
expert opinion, our research team hypothesized that signification variation exists 
in blood bank practices for SCD patients. To test this hypothesis, we developed 
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and performed a cross-sectional survey of hospital-based blood banks in North 
Carolina, with the following specific aims: 
1. To describe the current practices of hospital blood banks providing 
transfusion care to sickle cell patients; 
2. To describe factors that may influence these practices, and; 
3. To describe the use of NIH transfusion guidelines. 
The study described below attempts to provide new information to those 
caring for SCD patients, particularly blood bankers. We hope this study will 
serve to provide information to blood bankers about how their practices might 
' 
differ from their peers and evidence based literature and identity new 
opportunities to improve the delivery of transfusion therapy to this patient 
population. 
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METHODS 
Sample 
In order to conduct this cross-sectional survey of hospital-based blood 
banks in North Carolina (NC) to assess their current blood bank and transfusion 
practices for SCD patients, we first constructed a database ofNC hospitals that 
potentially provide services to this population. Using the data from the state 
hospital licensure files, the American Hospitals Association (AHA) directory, and 
the Medicare On-Line Certification and Reporting (OSCAR) files, we identified 
153 hospitals in NC. Hospitals that did not provide on-site blood banking, 
apheresis services, or both within their facility were excluded (N=l9). This 
included regional and local blood centers that provided contractual arrangements 
with hospitals for these services. Based on these criteria, 132 of 157 hospitals 
were initially selected for inclusion. We then excluded government-associated 
hospitals such as Veteran's Administration and Armed Forces hospitals and 
specialty hospitals providing care to only select, limited patient groups, i.e. 
Women's Hospital of Greensboro (N=26). The former were excluded because we 
hypothesized that standardization within these systems could potentially mask the 
variation in practice we sought to describe, the latter, as they were as they were 
unlikely to care for sickle cell disease patients. Finally, we also excluded the two 
academic hospitals, University of North Carolina Hospitals and Duke University 
Hospitals, which comprise a national Nlli Comprehensive Sickle Center. Rather, 
these hospitals were included in a subsequent study of blood bank practices at 
Nlli-funded Comprehensive Sickle Centers. Therefore, the final survey sample 
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was composed of 106 hospitals. 
Next, we used the membership roster of the American Association of 
Blood Banks (AABB), and information provided by the American Red Cross, 
Carolinas Region to obtain contact information for each hospital blood bank, the 
blood bank medical director, and laboratory supervisor. For each hospital, we 
selected two possible respondents, the blood bank medical director and the 
laboratory supervisor. The rationale for having two respondents per institution 
was based on our a priori hypothesis that each of these informants could provide 
unique and specific expertise relevant to different areas of the survey. We 
believed the blood bank medical director would provide the most accurate 
information on questions pertaining to clinical management and decision-making, 
while the laboratory supervisor could provide the most accurate information on 
questions relating to the day-to-day operations. Figure 2 illustrates the sampling 
methodology. 
The final mailing list contained the following identifying information: 
hospital name, phone number, and address; medical directors and laboratory 
supervisors' name, phone number, mailing address, and email address. Telephone 
screening of each hospital was performed to confirm the currency and accuracy of 
the contact information. 
All medical directors and laboratory supervisors at hospitals meeting the 
study criteria were mailed a self-administered, written survey accompanied by a 
cover letter describing the purpose of the survey, assuring confidentiality, and 
inviting participation. Each study participant was assigned a unique identification 
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number allowing data to be linked to an individual subject and the institution. 
The prefix ''ND" was used to indicate the North Carolina medical director; "NS" 
was used to indicate the North Carolina laboratory supervisor. 
Survey Design and Content 
The 30 minute, 35 item survey questionnaire was designed to assess six 
general content areas: 1) background demographic information of the hospital 
and blood bank, 2) respondent demographic characteristics, 3) the sickle cell 
population serviced by the hospitaVblood bank, 4) blood banking, transfusion, and 
apheresis practices and available services, 5) clinical management of SCD 
patients, and 6) availability and utilization of educational resources. To maximize 
the quality of information obtained on this wide range of topics, we used several 
response formats, including yes/no responses, single-item and multi-item 
responses, 4 and 5 point Likert-scale items, and open-ended responses. 
Additional information about the clinical management of SCD patients was 
collected using clinical vignettes that only the medical directors were asked to 
complete. The survey also collected information about individual respondent 
characteristics such as education/training, familiarity with NIH SCD Management 
guidelines, and opinions about consensus with transfusion guidelines. 
Pre-testing 
A draft survey instrument was pre-tested to address face validity, content, 
clarity, individual item format, and overall questionnaire format. For pre-testing, 
we selected a non-random sample often (10) large community based and 
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university hospital blood banks in Michigan and Virginia. These sites were 
selected based on previous experience with the medical directors at these 
institutions (principal investigator) in the former, and hypothesized regional 
similarities in patient population and practice patterns in the latter. Each potential 
participant was called by the principal investigator and asked to participate in the 
pre-testing of the survey instrument. After obtaining verbal agreement to 
participate, each participant was mailed a packet containing a cover letter 
explaining the purpose of the survey and pre-testing, the draft survey instrument, 
and an evaluation/feedback form (APPENDIX A). Responses were received from 
5/10 participants (50% response rate). In summary, respondents indicated the 
content, format, and length of the survey instrument was appropriate but several 
questions were confusing. 
Next, the principal investigator contacted six national experts on the 
management of SCD patients (by telephone and email) to gather additional 
feedback on the clinical vignette section. These vignettes were composed of four 
case scenarios designed to assess different areas of clinical management of SCD 
patients. Medical directors were asked to select the single best response based on 
1) the information provided and, 2) how such a patient would be managed in their 
own hospital. Feedback from these experts confirmed the appropriateness of the 
content, format, and clarity of these four vignettes. 
Based on all of the pre-testing information, a final survey instrument was 
drafted. As a result of feedback, the entire lay out of the survey was revised, 
several items were deleted, the order and grouping of items were changed, and 
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responses categories were simplified. The final survey instrument and cover 
letters accompanying each wave of data collection can be found in Appendix B. 
Survey Administration 
A summary of the procedures for administration of this survey is 
described below. A survey packet containing a cover letter, survey, and return 
postage-paid envelope was sent to the blood bank medical director and laboratory 
supervisor at each of the 106 hospitals. One hospital had two laboratory 
supervisors so a total of total of213 surveys were mailed initially. Two weeks 
later, non-respondents were mailed a postcard reminder asking them to complete 
the sent survey. One month later, non-respondents received a second mailing of 
the survey packet. Two months after the first mailing, non-respondents received a 
third and final mailing of the survey packet. 
Coding and data entry were performed as the surveys were returned. 
Detailed information on survey tracking, coding, and data entry can be found in 
Appendix B-3. The principal investigator ensured that all appropriate policies and 
procedures are followed. This study was approved by the Schools of Medicine 
and Public Health Institutional Review Boards at the University of North Carolina 
at Chapel Hill. 
Measures 
The following variables were selected from the NIH monograph, The 
Management of Sickle Cell Disease, as measures of blood bank practices: 1) use 
of leukocyte-reduced RBCs and 2) sickle trait negative RBCs, 3) performing 
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patient RBC phenotyping, 4) providing this information to the patient or family, 
and 5) use of antigen matched RBCs. These measure were selected as concrete 
and directly measurable. NIH guidelines were used as our source because it was 
felt that they not only reflected the opinions of the authors ofthe earlier consensus 
but also other health professionals involved in the care of SCD patients. 
Specifically, NIH guidelines state the following: 14 
I. All blood should be screened for the absence of sickle cell trait. 
2. Prestorage leukodepletion of red cells is standard practice to reduce febrile 
reactions, platelet refractoriness, infections, and cytokine induced 
complications. 
3. The antigenic phenotype of the red cells (at least ABO, Rh, Kell Duffy, 
K.idd, Lewis, Lutheran, P, and MNS) should be determined in all patients 
older than 6 months of age. 
4. A permanent record of the phenotyping should be maintained in the blood 
bank to optimize matching, and a copy of the record should be given to the 
patient or family. 
5. Limited matching for E, C, and Kell [sic] antigens is usually performed, 
unless patients have antibodies. 
Figure 3 describes each guideline and its corresponding survey item(s). 
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Next, we developed a model of the delivery of transfusion care to SCD 
patients in which the blood bank was an independent factor (Figure 2). We 
hypothesized both external (hospital level) and internal (blood bank level) factors 
might affect the blood bank's ability to deliver transfusion care to SCD patients. 
Figure 3A-B illustrates these possible factors. The survey instrument measured 
The survey instrument measured the following external factors: hospital type 
(academic, community, other), presence of a trauma center and number ofRBC 
units transfused/year (surrogate markers of hospital size/complexity), 
identification of a sickle cell patient to the blood bank prior to transfusion. 
Internal blood bank factors measured were specific policies/procedures for SCD 
patients; blood bank capabilities measured by offered services such as simple 
transfusions, exchange transfusions and a chronic transfusion program, testing 
(perform phenotyping of patient RBCs and communication of results to patient or 
family), blood product selection (age ofRBC, special RBC products), clinical 
management ofSCD patients in that institutions (clinical vignettes), opinions on 
whether clear consensus exists on the management of SCD patients, and finally, 
training and educational resources (availability, conference attendance, sources of 
SCD information). 
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Analysis 
Because the hospital was the unit of analysis, survey responses received from 
either the blood bank medical director or the laboratory supervisor were 
considered a positive response. If responses were received from both respondents 
at a single institution, we preferentially selected the medical director's survey for 
inclusion. This method allowed us to include clinical management of sickle cell 
patient as an independent variable. We also excluded surveys with> 10% 
missing data. In that case, the more complete of the two responses was selected 
for analysis. 
The descriptive analyses are reported as percentages of the total number of 
surveys used in the analysis for categorical variables; normally distributed 
continuous variables are reported as means and ranges. For non-parametric 
continuous variables, medians and ranges are reported for a more accurate 
depiction of the data. 
Finally, in order to provide a general assessment of use of NIH transfusion 
guidelines by blood banks in NC, were-categorized the five measures selected 
from the NIH monograph into dichotomous variables based on clinical 
significance or positive (affirmative) and negative responses. Descriptive 
analyses were performed using a standard statistical software program (STAT A, 
8.0, Stata Corporation, College Station, TX). 
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RESULTS 
Of the 106 hospital blood banks surveyed, 76 returned completed or nearly 
complete surveys, 9 returned invalid or incomplete responses, and three surveys 
(3) were returned undeliverable, for a final response rate of 80.4% (8511 06). 
Excluding invalid/incomplete surveys, a total of76/106 surveys (70% of sample) 
were included in the analysis. The individual response rate was 55.4% (115/213). 
Characteristics of the hospitals, blood banks/transfusion medicine services, 
respondents, and sickle cell population are reported in Table 1. 
Nearly all of the hospitals in our sample were community-based (90%); 
approximately 5% were university or university-affiliated hospitals. The majority 
of hospitals (82%) did not have a trauma center. Ofthose that did, only 5% were 
Levell trauma centers. Hospitals in our sample were representative of hospitals 
inNC. 
As described in the methods, we sampled two respondents per hospital, 
the medical director and the laboratory supervisor. On average, laboratory 
supervisors responded twice as frequently as the medical directors (70% vs. 30% ). 
All medical directors had doctorates in medicine or osteopathy; a minority also 
had an additional graduate degree (5%). The majority had medical training in 
hematology/oncology or pathology (91 %). One fourth of these physicians also 
had subspecialty training in blood banking/transfusion medicine. Nearly all of the 
laboratory supervisors were medical technologists (85%) and about one quarter 
had obtained sub-specialty certification in blood banking (SBB) (22%). 
Hospital blood banks transfused a median of 1943 RBC units per year 
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(range= 30-26,000 units). North Carolina blood banks provided services for 0-30 
SCD patients per month (median= 1 ). The percentage of sickle cell patients 
younger than 21 years of age, ranged from 0 to 100% (median= 15%). Thus, 
most blood banks transfused a small number ofRBC units per month, and 
encountered few SCD patients per month. The majority of these were adults 
patients 
Blood bank practices such as specific policies/procedures, offered 
services, and testing, are reported in Table 2. About one third of hospitals had 
specific policies/procedures for the work-up of a sample from a SCD patient and 
for the distribution of blood products to SCD patients. These practices did not 
appear to depend upon whether a patient was new or already known to the blood 
bank (88.3%). All blood banks offered simple transfusion ofRBCs. Few offered 
manual RBC exchange transfusions (16%) and even fewer offered automated 
RBC exchanges (6.6%) or chronic exchange transfusion programss (6.9%). 
Although the majority ofNC blood banks performed patient RBC phenotyping 
( 69% ), few patients or families received the results ofthis testing ( 16% ). 
Table 3 shows the frequency and types ofRBCs routinely used for SCD 
patients. The majority of our sample typically provided RBCs that were less than 
or 14 days old to their SCD patients. About 16% provided RBCs less than 7 days 
old. The vast majority of blood banks in our sample routinely provided leukocyte 
reduced RBCs to SCD patients (91% always or sometimes). Few routinely 
provided washed, irradiated, or frozen RBCs. Finally, nearly two-thirds ofNC 
hospital blood banks did not routinely provide, antigen-matched RBCs to SCD 
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patients (62%). Of those that did about half provided these units before a patient 
was transfused. 
Respondents indicated that several external factors affected their practices 
for SCD patients. These included the frequency in which SCD patients were 
identified to the blood bank prior to transfusion, availability of compatible units, 
and cost. Identification of SCD patients to the blood bank prior to transfusion 
was fairly poor. In our sample, 52% indicated patients were always or often 
identified, 21% sometimes identified, and 27% rarely or never identified. When 
asked how difficult it was to obtain compatible RBC units for SCD patients, 9% 
indicated that it was very difficult, 57% indicated it was somewhat difficult, and 
34% indicated it was not difficult at all. Finally, only 16% of the respondents 
indicated that cost affected their practices. When asked if cost were not an issue 
would their practices change, the overwhehning majority said no (83%). 
Internal factors, measured in the survey were clinical management of 
sickle cell patients, consensus with transfusion guidelines, training, and 
availability/utilization of educational resources. There was significant item non-
response for these questions. As previously described, only medical directors 
were asked to complete the section on clinical management of SCD patients 
within their institutions. Only 50% of medical directors completed this section. 
Therefore, these results were omitted from this paper. Approximately 75% of 
hospitals provided information on consensus, training, and education. Although 
results are not available for 25% of hospitals, we examined these items to identify 
possible trends and opportunities for future interventions. These results are 
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described below. 
We originally postulated that blood bank practices could be influenced by 
the perception that clear consensus existed for different aspects of managing SCD 
patients. Approximately 50% of respondents indicated that there was clear 
consensus with the selection of blood products for SCD patients, indications for 
transfusion therapy, and the use of phenotypically matched (antigen matched) 
RBCs. However, the majority (70%) did not feel there was clear consensus on the 
use of a chronic transfusion program. The actual percentages of respondents who 
agreed and disagreed as well as their level of agreement/disagreement for each of 
these items can be found in Table 4. 
Similar results were found for items related to education and available 
resources (Table 5). Half of the respondents felt their training had prepared them 
to manage the needs of SCD patients and that blood bank/transfusion information 
for SCD patients was readily available. The majority of respondents (65%) were 
not familiar with the NIH monograph, Management of Sickle Cell Disease. This 
finding is not surprising given the fact that no study respondents cited the NIH as 
a source of information about the management of SCD patients. 
The most frequently listed resources for blood bank/transfusion 
information on SCD patient management by respondents in this sample are 
described in Table 6. Pathology professional societies were the most utilized 
source (39%) of information for blood bankers; the American Association of 
Blood Banks represented the bulk of this category. Consultation with 
hematologists and other hospital blood banks was cited as the next most common 
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source (21% ). The remainder of sources (in decreasing order of frequency) 
included the American Red Cross (17%), the Internet (11 %), conferences (6%) 
and other (5%). No respondents cited the NIH as source of information about 
SCD. 
Finally, a few respondents provide feedback about their concerns in 
managing SCD patients via responses to open-ended questions. A sample of 
these written comments follows: 
• "if we knew what the consensus was on what to do" and "we see so few 
patients" 
• "if we know specific needs of our sickle cell patients we'd want to do all that 
we can to help" 
• "currently we have very few sickle cell patients with time and info, we would I 
' 
perform prophylactic antigen typing" 
• "We have a very low number of sickle cell patients. Most are referred out." 
• "We have no protocol, are not consulted. For the most part, SS patients are 
transferred." 
• "Patient management [is] under control of hematologist, not BB Medical 
Director" 
• "Would love to be informed of continuing education re: SCD." 
• "These patients would most likely be transferred to a larger facility." 
• "Our hospital is very small; we would always try to get these patients to a 
larger facility." 
• "Need guidelines for transfusion selection/crisis management/diagnosis. 
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Standards change per region." 
• Provide special units "if ordered by MD." "Provide leukocyte reduced units if 
certain physicians order them." 
• "May look at current practice of local area and see if we need to update our 
policy." 
• "Antigen negative blood from ARC [American Red Cross} is too expensive to 
phenotypically match every sickle cell patient. Would phenotypically match 
sickle cell patients if antigen blood from ARC wasn't so expensive." 
• "Computer system doesn't display patient diagnosis; we don't know we are 
transfusing a SCD patient." 
• "Heme/one docs manage our rare HbSS patients." 
• "Test patient for Fya, Fyb, Jka, Jkb, S, s but do not provide units negative due 
to cost/availability." 
• "Adult and peds [patients] are treated differently" 
• "Blood Bank doesn't know if patient has SCD; patients managed by their 
MD's." 
• "Never had a SC patient. Only have 1 family of African Americans in our 
community." 
• "I would like to know what the best practices are for management of sickle 
cell patients." 
• "If they have antibodies, they are going to another area." 
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DISCUSSION 
This descriptive study provides the first comprehensive glimpse of how 
blood banks are currently managing transfusion therapy for SCD patients. 
Findings from this study support the notion that the hospital blood bank is a 
source of variation in the delivery of transfusion care to this patient population. 
In addition, they further strengthen our contention that opportunities exist to 
improve this care by interventions designed to address factors that affect the blood 
bank's ability to deliver transfusion therapy. This study also suggests that Nlli 
transfusion guidelines are not a source of information for blood bank personnel. 
These results provide important and useful information to consider in the design 
of future interventions to improve the delivery of transfusion therapy to SCD 
patients 
Our study confirms previous findings that variation exists in the use of 
specific blood products for SCD patients. Blood banks appear to uniformly 
provide leukocyte reduced RBCs (92%) to these patients but not antigen matched 
blood. In our sample, approximately 30% of blood banks provided antigen 
matched at any time to SCD patients. This finding is consistent with the results of 
a 2004 College of American Pathologists' survey of 1172 accredited laboratories 
in the US67 but contrasts with another that showed 73% of academic medical 
centers in the US and Canada provide antigen matched blood to SCD patients 
prior to transfusion. 66• 67 Availability of these units has been cited as a limiting 
factor to this practice.49 Nearly two-thirds of our sample indicated that getting 
compatible, antigen matched blood was very or somewhat difficult. Given the 
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fact that nationally, over the past 30 years the percentage of African American 
donors has remained at less than I 0%50' 68'70the use of antigen matched blood for 
SCD patients may still not be feasible for most blood banks. Costs associated 
with routinely providing antigen- matched blood to SCD patients have also been 
cited as a barrier to widespread implementation of this practice. 39 It is estimated 
that antigen matched units are on average 1.5 to 2 times the cost of a usual RBC 
unit.47 In this study, cost did not appear to be a barrier as only 16% of our 
sample described cost as influencing their practices. 
Although there is no published data that we are aware of to compare with 
our finding that 52% of blood banks in NC always or sometimes provide sickle 
cell trait negative blood, anecdotally we know that it is standard practice among 
many blood banks to only screen RBC units for sickle cell trait when providing 
these units for manual or automated exchange transfusions (7% in our sample). In 
this case, pre and post transfusion monitoring ofHbS is important to determine if 
the goals oftherapy were met. With the current composition of donors, roughly 9 
out oflO RBC units will be negative for sickle cell trait. In light of this fact, the 
utility of screening every blood unit of for sickle cell trait becomes questionable. 
Therefore, our results may represent a significant underestimation of the 
frequency in which SCD patients actually receive sickle trait negative blood. 
Our study also suggests that communication between patients, clinicians, 
and blood bank personnel could be improved. Our finding that less than 1/3 of 
blood banks who phenotype patient's RBC then provide these results to SCD 
patients and/or their families has not been previously reported. This is alarming as 
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SCD patients are already at high risk for alloimmunization and potentially severe 
transfusion reactions. Documentation of these results in patients' medical records 
may not be inadequate protection for SCD patients who receive care at multiple 
institutions. More frequent identification of SCD patients to the hospital blood 
bank prior to transfusion may help ensure that the blood bank utilizes all available 
resources for these patients. 
As in other areas of medicine, little is known about the use of practice 
guidelines. In our study blood bankers, did not consider the NIH to be a 
definitive source of information about managing SCD patients. In addition, most 
felt that consensus did not exist on how to managing these patients. One possible 
reason for this finding may be disagreement about the evidence for various 
I 
! practices. This has been true for the practice of prophylactically providing 
antigen matched RBCs. Some authors have suggested the need for a randomized 
control trial comparing outcomes in patients receiving prophylactic antigen 
matched RBC vs. those who do not.38 Our findings support the need for this 
future study. Additional reasons for our findings may include 1) a lack of 
involvement by blood bankers in the development and dissemination of 
information pertaining to transfusion therapy, 2) lack of participation in 
educational activities about SCD, and 3) lack of knowledge about the practices of 
their peers. Further work is need to elucidate whether increased awareness of the 
NIH guidelines will result in increased us by blood bankers. exists for 
management of SCD patients. for the latter may include Practice guidelines are. 
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Limitations 
Our study has several limitations. First, these results are only descriptive 
and should therefore be considered preliminary. Further planned analyses will 
include testing for non-response bias, assessment of correlation between 
variables, and multivariate analysis. The small sample size relative to the number 
of variables will likely preclude the use of modeling data for a specific outcome. 
The results of these analyses will provide a more complete view of our study 
findings. Furthermore, the study design, a cross-sectional survey, provides only 
limited information about this complex issue. An inherent limitation of this 
design is that causality cannot be assessed. 
As previously mentioned, NC is a unique state for the treatment and 
management of SCD patients. Therefore our results may not generalizable to 
other states. The effect of having a longstanding statewide program and an Nill 
Comprehensive Sickle Cell Center on blood bank practices was not assessed in 
this study. However, we know from discussions with the state program manager 
that education to health professional in this state has not included blood bank 
personnel. The large SCD population in NC may also have affected the quality 
of our data. Our sample was possibly already attuned to the needs of SCD 
patients so interest in participating in this study was much higher than could 
otherwise be expected. 
Next, our selection ofNC hospitals may have also affected the quality of 
our data. Hospitals that currently provide transfusion care to sickle cell patients 
may have been inadvertently excluded based on our inclusion/exclusion criteria. 
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We intentionally excluded the two large academic centers that comprise NIH 
Comprehensive Sickle Cell Center to minimize bias in our data. As a 
consequence, blood bank practices for nearly 1400 SCD patients who receive care 
through this combined center are not represented in our study. In addition, we do 
not know the extent to which practices these two institutions reflect those in the 
rest of the state. 
Finally, the quality of our data may also have been affected by our 
sampling strategy of two possible respondents per hospital. Based on our a priori 
hypothesis that the medical director was the better of the two informants, we 
preferentially used data from this respondent. In actuality, medical directors were 
more often non-respondents and more likely return incomplete survey, which in 
tum, hindered our ability to obtain information about clinical management of 
SCD patients in each institution. Therefore, data from these respondents may not 
accurately reflect those of the laboratory supervisor. However, several of the 
surveys sent to the medical director were completed and returned by the 
laboratory supervisor; comments on a few of these surveys were "it was felt that 
only one response was necessary." Accurate comparison of the responses by 
blood bank medical directors vs. laboratory supervisors may not be possible. Our 
response rate and rate of item non-response, may have due to the length and 
comprehensiveness of the survey instrument of survey. This most likely required 
respondents to actively seek out information they may not have already known or 
had readily available. 
Despite these limitations, our study provides the useful information about 
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the delivery of transfusion therapy to SCD patients in NC. Variation in blood 
bank practices may be factor in the quality of transfusion care SCD patients 
receive. Further studies are needed to confirm whether our findings are 
representative of state, regional, and national practices. Additional studies 
should also attempt elucidate the possible impact of this variation on patient 
outcomes. Finally, improved collaboration and communication among all health 
professionals caring for this patient population may be one unrealized, yet 
important, opportunity to improve the delivery of transfusion care. 
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Figure 1. Mechanism of Alloimmnnization 
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Figure 1. Schematic diagram of alloimmunization in SCD patients. (A) Native 
sickle cells tend to lack red cell antigens. (B) After transfusion, two populations of red 
cells exist. The normal (donor) red cells have surface antigens. (C) The body then 
recognizes the antigens on these cells as foreign and develops antibodies against them. 
Figure 2. Patient Interactions with Health Care System 
Clinician Blood Bank 
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Figure 3. Factors Affecting Transfusion Delivery to SCD Patients 
3A. Hospital and Blood Bank Level Factors 
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3B. External and Internal Factors 
Blood Bank Practices 
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Hospital size & complexity 
Number of SCD patients 
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Product Availability 
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Size & Complexity 
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Figure 4. Sampling Methodology 
C Hospitals without blood bank (N=l9) ~ 
~f--------•... CGovernment!Specialty Hospitals.(N=26) ~ 
C Duke/UNC NIH Sickle Center (N=2) ~ 
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Figure 5. Guidelines with Corresponding Survey Items 
• NIH Guideline: All blood should be screened for the absence of sickle cell 
trait. 
• NIH Guideline: Presto rage leukodepletion of red cells is standard 
practice to reduce febrile reactions, platelet refractoriness, infections, and 
cytokine-induced complications. 
Corresponding Survey Items: 
The following is a list ofRBC products that a Blood Bank might provide for a 
sickle cell patient. Please indicate how often each of the following products is 
provided for a sickle cell patient in your hospital. 
Blood Product Always Sornetirn Rarely Never 
es 
a. Non-leukocyte reduced RBCs 3 2 1 0 
I, Leukocyte Reduced RBCs .. 3 .• 2 I ·. 0 
c. Irradiated RBCs 3 2 1 0 
d. WashedRBCs 3 2 1 0 
.. Sickle cell trait negative RBCs 3 . 2 1 0 
f. FrozenRBCs 3 2 1 0 
g. Other: 3 2 1 0 
• NIH Guideline: The antigenic phenotype of the red cells (at least ABO, 
Rh, Kell, Duffy, Kidd, Lewis, Lutheran, P, and MNS) should be 
determined in all patients older than 6 months of age. 
Corresponding Survey Item 
Do you perform patient RBC phenotyping ... ? (Choose one) 
1. Before transfusion of blood products 
2. After transfusion of blood products 
3. After development of an antibody 
4. No typical procedure 
5. Not performed 
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NIH Guideline: A permanent record of the phenotyping should be 
maintained in the blood bank to optimize matching, and a copy ofthe record 
should be given to the patient of family. 
Corresponding Survey Item 
Do you provide this phenotyping information to the patient? 
0. No 
1. Yes 7 please describe how 
• NIH Guideline: Limited matching forE, C, and Kell [sic] antigens is 
usually performed, unless patients have antibodies. 
Corresponding Survey Items 
C-8. Does your Blood Bank routinely provide phenotypically matched 
RBCs for sickle cell patients? (Choose one) 
1. Yes, perform pre-transfusion prophylactic antigen matching. 
2. Yes, perform prophylactic antigen matching after patient makes an 
antibody. 
3. No, do not perform prophylactic antigen matching. (i.e. only honor 
antibodies patient has already made) --> Skip to question C-1 0 
C-9. Please circle the specific antigens that your blood bank prophylactically 
matches for. 
Blood Groups Specific Antigens 
Rh D c c E e 
Kell K k 
Duffy Fya Fyb 
Kidd Jka Jkb 
MNS M N s s u 
Others: Please list 
Page 37 of 47 
Table 3. Sample Characteristics (N=76) 
Hospital Characteristics N 
Practice Setting 
Community Hospital 68 89.5% 
University or Affiliate Hospital 4 5.3% 
Other 4 5.3% 
Trauma Center 13 18.0% 
Level 1 Trauma Center 4 5.3% 
Blood Bank/Transfusion Service 
Number ofRBC units transfused per year (median) 69 1943 (range) 817-3977 
Respondent Characteristics 
Medical Director (MD or DO) 22 30% 
Education & Training 
Pathology 
Anatomic pathology only 20 90.9% 
Anatomic and clinical pathology 18 81.2% 
Other graduate degree (PhD or Masters) 1 5.5% 
Sub-specialty training 
Blood Bank/Transfusion Medicine 5 25% 
Hematology/Oncology 20 90.9% 
Laboratory Supervisor 53 70% 
Education & Training 
Medical Technologist degree 49 92% 
Specialty training in Blood Banking (SBB) 12 22% 
Other degree or certification 1 1.8% 
Sickle Cell Population 
Number of sickle cell patients seen per month (median) 70 1 (range) 0-30 
Percentage of sickle cell patients < 21 years of age 15% (median) 68 0-100% (range) 
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Table 4. Blood Bank Practices (N=76) 
N % 
Policies/procedures 
Have policies/procedures for the work-up ofSCD patients 22 29 
Have policies/procedures for blood distribution to SCD patients 25 33 
Practices differ if new patient 9 12 
Offered Services 
Simple transfusion 76 100 
Manual exchange transfusion 12 16 
Automated exchange transfusion 5 7 
Chronic transfusion program 5 7 
Blood Bank Testing 
Perform patient RBC phenotyping 52 69 
Provide phenotyping information to patient/family 11 16 
Table 5. Types and Frequency ofRBCs Used (N=76) 
Always Sometimes Rarely Never 
RBCProduct 
Non-leukocyte reduced RBCs 3.2% 6.5% 3.2% 87.1% 
Leukocyte Reduced RBCs 86.1% 5.6% 4.2% 4.2% 
Irradiated RBCs 0% 16.4% 31.2% 52.5% 
WashedRBCs 0% 4.9% 44.3% 50.8% 
Sickle cell trait negative RBCs 41.5% 10.8% 9.2% 38.5% 
FrozenRBCs 0% 13.3% 30.0% 56.7% 
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Table 7. Use of Transfusion Guidelines (in decreasing order offreqnency) 
Guideline N % 
Leukocyte reduced RBCs (always/sometimes) 71 92 
Perform patient RBC phenotyping 74 69 
Sickle cell trait negative RBCs (always/sometimes) 39 52 
Provide antigen matched RBCs for C, E, and Kell 23 30 
Provide phenotyping results to patient 69 16 
Table 8. Agreement with Consensus (N=55) 
Strongly Agree Disagree Strongly Agree Disagree 
There is clear consensus ou ... 
. . . the selection of blood products for 9.3% 35.2% 48.2% 7.4% 
sickle cell patients . 
. . .indications for transfusion therapy 5.5% 41.8% 50.9% 1.8% for sickle cell patients . 
. . . phenotypic matching of blood 12.7% 34.5% 47.3% 5.5% products for sickle cell patients . 
. . . the use of chronic transfusion (i.e. 
hypertransfusion) programs for 2% 28% 66% 4% 
sickle cell patients. 
Table 8. Agreement with Education and Training (N=55) 
Strongly Agree Disagree Strongly Agree Disagree 
Education/Training 
My training prepared me to manage 10.9% 38.2% 47.3% 3.6% 
the needs of SCD pts. 
Blood bank/transfusion information 8.9% 42.9% 42.9% 5.4% 
for SCD pts. is readily available. 
I am familiar with the NIH 
publication, Management of Sickle 5.5% 29.1% 54.6% 10.9% 
Cell Disease. 
Table 9. Sources of Information about SCD (in decreasing order of 
frequency) 
N % 
Source (N=53) 
American Association of Blood Banks 18 34 
Peer-Reviewed Literature 18 34 
Consultation (hematologists/other hospitals) 11 21 
American Red Cross 9 17 
Internet 7 11 
Conferences 4 6 
College of American Pathologists 3 5 
Other 3 5 
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APPENDIX A-1: Draft Survey 
TRANSFUSION MANAGEMENT OF SICKLE CELL PATIENTS SURVEY 
ROBERT WOOD JOHNSON CLINICAL SCHOLARS PROGRAM, 
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 
and 
UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER IN GAINESVILLE 
STATEMENT OF CONFIDENTIALITY 
The identification number allows us to keep track of the questionnaires as they are returned. Any 
information that would permit identification of an individual or a practice organization will be held 
strictly confidential, will be used only for the purposes of this study, and will not be disclosed or 
released to other persons or used for any other purposes, 
Which of the following services does your hospital provide (Circle only !ill!) 
L Blood Banking Only J 
2. Blood Banking and Therapeutic Pheresis Services 
3. Therapeutic Pheresis Services Only 
Please continue with the survey 
4. None of the Above ~Please indicate who provides these services for your hospital. 
If you circled item# 4, do not answer any further survey questions. Return this survey in the 
enclosed self-addressed envelope to ensure that you are removed from our list. We thank you for 
your time. 
Transfusion practices for sickle cell patients 
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APPENDIX A-1: Draft Survey 
A. Background and Professional Practice 
A-1. What is the zip code of your facility? ____ _ 
A-2. Which of the following best describes your practice site? (Choose one) 
1. University Hospital 
2. University Affiliate 
3. Community Hospital 
4. Local Blood Center 
5. Regional Blood Center 
6. Other (Please describe). __________ _ 
A-3. What is your current position? 
1. Medical Director 
2. Assistant Medical Director 
3. Laboratory Supervisor 
4. Medical Technologist 
5. Other (Please describe) __________ _ 
A-4. Which of the following describes your professional training? (Circle all that apply) 
a.MT b. SBB c. MD or DO d. PhD e. Other: _____ _ 
A-5. If you are an MD or DO, which of the following best describes your medical training? 
(Circle all that apply) 
a. Hematology/Oncology 
b. Anatomic Pathology Only 
c. Anatomic and Clinical Pathology 
d. Blood Banking/Transfusion Medicine 
e. Other (please describe), __________ _ 
B. Facilities and Sickle Cell Pooulation 
B-1. How many units of Red Blood Cells (RBCs) did you transfuse at your hospital last year? 
________ units/year 
B-2. Are you a Trauma Center? 
1. No 2. Yes, (please indicate what level _______ _; 
The following questions refer only to patients with known Sickle Cell Disease (SCD), including patients 
with genotypes such as HbSS, HbSC, HbS-thal, etc. 
B-3. Please estimate the number of sickle cell patients your service supports each month. 
_____ .SCD pts /month 
Transfusion practices for sickle cell patients 
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APPENDIXA-1: DraftSurvey 
B-4. What percentage of your sickle cell patients are under 21 years of age 
_____ %? 
C. Blood Banking Practices 
C-1. Do you have policies/procedures specific for ... (Please circle YES or NO for each item) 
a. the Blood Bank work-up of sickle cell patients? 
b. the distribution ofRBCs to sickle cell patients? 
0. NO 
0. NO 
I. YES 
I. YES 
C-2. Do your practices differ if a sickle cell patient is ... (Please circle YES or NO for each item) 
a. New to your hospital? 
b. Known to your hospital? 
0. NO 
0. NO 
I. YES 
I. YES 
C-3. How frequently are sickle cell patients identified prior to transfusion? (Choose!!!!£) 
a. Always b. Often c. Sometimes 
C-4. Do you perform patient RBC phenotyping ... ? (Choose l!!!t) 
I. Before transfusion of blood products 
2. After transfusion of blood products 
3. After development of an antibody 
4. No typical procedure 
5. Not performed 
d. Rarely e. Never 
C-5. The following is a list ofRBC products that a Blood Bank might provide for a sickle cell patient. 
Please indicate how often each ofthe following products is provided for a sickle cell patient in your 
hospital. 
Blood Product Always Sometimes Rarely Never 
a. Non-leukocyte reduced RBCs 3 2 1 0 
b. Leukocyte Reduced RBCs 3 2 1 0 
c. Irradiated RBCs 3 2 1 0 
d. WashedRBCs 3 2 1 0 
e. Sickle cell trait negative RBCs 3 2 1 0 
f. FrozenRBCs 3 2 1 0 
g. Other 3 2 1 0 
C-6. What is the average age of the RBCs your Blood Bank provides to sickle cell patients? 
(Choose l!!!t) 
I. <2 days 2. 3-5 days 3. 5-7 days 4. >7 days 5. > 10 days 6. >14 days 
Transfusion practices for sickle cell patients 
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C-7. Does your Blood Bank routinely provide phenotypically matched RBCs for sickle cell 
patients? 
L Yes, limited matching 
2. Yes, extended matching 
3. No, not until the patient makes an antibody (Skip to question C-9) 
C-8. Please list the antigen groups that your Blood Bank matches for in each case. 
C-Sa. Limited matching: ~~~~~~~~~~~~~~~~~~~~~~~~ 
C-Sb. Extended matching: ~--~~-----~~---------~ 
C-9. How difficult is it to obtain phenotypically matched blood for SCD patients? 
l. Very Difficult 2. Somewhat difficult 3. Not difficult at all 
C-1 0. Does cost influence your current practices/policies? 
0. No 
I. Yes (please describe) ______________________ ~ 
D. Transfusion Therapy 
D-1. Which of the following are performed at your hospital? (Circle all that apply) 
a. Simple transfusion 
b. Manual Exchange Transfusion 
c. Automated Exchange Transfusion 
D-2. Do you have a Chronic Transfusion Program at you hospital? 
I. Yes 0. No ~Please skip to section E 
The following questions refer to patients who are enrolled in your Chronic Transfusion Program. 
D-4. What types of patients are in your Chronic Transfusion Program? (Circle all that apply) 
a. Sickle Cell Disease 
b. Thalassemia 
c. Other inherited RBC Diseases 
d. Acquired RBC Diseases 
e. Other __________ ~ (please indicate) 
D-5. Please indicate the types of therapy and average frequency of therapy provided to patients in your 
Chronic Transfusion Program. (Circle all that apply) 
a. Simple Transfusion ............................................. Every~~~~- weeks 
b. Manual Exchange Transfusion ................................. Every weeks 
c. Automated Exchange Transfusion ............................ Every weeks 
d. Other (please indicate) ......... Every weeks 
Transfusion practices for sickle cell patients 
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E. Transfusion Practices: Clinical Vignettes 
This section of the survey is to be completed by the medical director. If you are a laboratory supervisor, 
please skip ahead to Section F. 
Ewl. A 16 y.o. with sickle cell anemia is scheduled for laparoscopic cholecystectomy. The baseline CBC 
reveals Hct 22% and the Hgb electrophoresis reveals 95% Hb S, 2% Hb A2, and 3% Hb F. 
You recommend the following ... (Circle one) 
1. Perform an exchange transfusion to reduce the Hb S fraction to 30%. 
2. Transfuse RBCs to a Hct of30%. 
3. Transfuse RBCs to a Hct of36%. 
4. No transfusion is indicated. 
E-2. A 7 y.o. girl with known sickle cell anemia (Hb SS disease) presents to the Emergency Department 
with a 12-hour history of abdominal pain, nausea, vomiting and lethargy. Physical examination 
reveals an easily palpable and tender spleen. The CBC shows a WBC count of 29,000/uL with 80% 
neutrophils and 12% bands, Ret 12%, PLT- 88,000/uL. The physician in charge requests assistance 
in transfusion recommendations. 
E-3. 
You recommend the following ... (Circle one) 
l. Simple transfusion of packed RBCs 
2. Perfonn an automated exchange transfusion 
3. Perfonn a manual exchange transfusion 
4. Transfusion is not indicated 
A 28 y.o. woman with Hb SC disease has acute chest syndrome with progressive hypoxemia. The 
ICU physician caring has requested transfusion ofRBCs for the patient. Review of the CBC reveals 
WBC 22,000, Hct 28%, platelet count 530,000. 
You recommend the following ... (Circle one) 
1. Simple transfusion of3 U PRCs 
2. Exchange transfusion with target Hct 36% 
3. Exchange transfusion with target Hct 28% 
4. No transfusion is indicated 
E-4. Eight days ago a 29 y.o. African American man with sickle cell anemia (Hb SS) was transfused 2 
units ofRBCs for treatment of hypoxia. He was discharged from the hospital4 days ago and now 
returns complaining of severe pain of his anns, legs, and back. On physical exam his sclerae are 
icteric and his abdomen is mildly tender in all quadrants. His Hct upon discharge was 26% and now 
it is 14%. He was previously known to have anti-C and anti-K antibodies and on this evaluation there 
is a newly identified anti-S antibody. 
You recommend the following ... (Circle one) 
1. Transfuse 2 units of compatible RBCs 
2. Perfonn therapeutic plasmapheresis 
3. Perfonn an exchange transfusion with compatible RBCs 
4. Supportive care and avoid RBC transfusion 
Transfusion practices for sickle cell patients 
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F. Educational Resources 
F-1. My training has prepared me to manage the transfusion needs of 
sickle cell patients. 
F-2. There is a clear consensus on the management of sickle cell patients. 
F -3. Information on the management of sickle cell patients is readily 
available. 
F -4. In the past 2 years, I have attended at least one conference or 
presentation on the management of sickle cell disease. 
F-5. I am aware of the Management and Therapy of Sickle Cell Disease 
guidelines provide by the National Institutes of Health 
0. NO 
0. NO 
0. NO 
0. NO 
0. NO 
F-6. How do you obtain current information on the management of sickle cell patients? 
1. YES 
1. YES 
1. YES 
1. YES 
1. YES 
F-7. Is there anything else about your care of sickle cell patients that you would like to share with us? 
Please indicate below if you would like to receive a summary of the study results. 
Yes, I would like to receive a copy of the study results. 
Thank you for completing this survey! 
Please return this survey in the enclosed, prepaid envelope to: 
Araba Afcnyi-Annan, MD 
Robett Wood Johnson Clinical Scholars Program 
University of North Carolina ai Chapel Hill 
5034 Old Clinic Building, CB# 71 05 
Chapel Hill. NC 27599-7105 
Phone: (919) 966-3798 Fax: (919) 843-9237 Email: nyaniba@mecLunc.edu 
© 2003 Araba Afenyi-Annan 
Transfusion practices for sickle cell patients 
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Dear Colleague, 
Thank you for agreeing to participate in this pilot test. Your feedback is very important 
to us; it will be used to reshape and refine the final survey instrument. Your candor and 
suggestions for improvement will help us ensure the quality of data we obtain from this 
study. 
This study is being conducted by researchers at the University of North Carolina Robert 
Wood Johnson Clinical Scholars Program/Department of Pathology, Transfusion 
Medicine Service, the Cecil G. Sheps Center for Health Services Research at the 
University of North Carolina, and the University of Florida, Gainesville, Department of 
Medicine, Division of Hematology/Oncology. The purpose of this study is to assess the 
practice variation that occurs in the blood bank/transfusion medicine management of 
sickle cell disease patients and identify areas for future interventions. The target 
audience of this study is blood bank/transfusion medicine medical directors and/or 
assistant medical directors as well as the blood bank laboratory supervisors. We intend to 
survey all hospitals in the state of Florida and North Carolina.that provide service to 
sickle cell patients. This study is currently awaiting IRB approval. 
Please see enclosed a draft survey, a comment sheet, and a self-addressed, postage paid 
envelope for your convenience. The identification number on your survey is used to 
track the questionnaires as they are returned. Your responses and feedback will be held 
strictly confidential and no identifying information will be disclosed or released to other 
persons or used for any other purpose. Finally, the information that you provide will not 
used in our data analysis. 
Thanks again for your help on this project. If you have any other questions or concerns, 
please do not hesitate to contact me. 
Sincerely, 
AAA (please leave room for my signature)! 
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Now that you have completed the survey, we would appreciate your feedback. Your 
comments will help us learn how we can alter the survey to best serve our purposes. 
This is your opportunity to help us improve care to sickle cell disease patients. 
1. How long did it take to complete the survey? 
2. Is the survey.. . (Circle one) 
too long? too short? appropriate length? 
3. Is the survey understandable? 
Yes No 
4. Are the questions clear? (Circle one) 
Yes No 
5. Is the content appropriate for the intended audience? 
Blood Bank Medical Director 
Laboratory Supervisor Yes 
Yes No 
No 
6. Is there additional content you feel should be included in the survey? 
No 
Yes (please indicate)---------------------
7. What is your preferred method for receiving this survey? (Circle one) 
Mail Log in to secure website No preference 
8. Do you have any suggestions that might improve our response rate? 
9. Do you have any additional comments? 
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TRANSFUSION MANAGEMENT OF SICKLE CELL PATIENTS SURVEY 
ROBERT WOOD JOHNSON CLINICAL SCHOLARS PROGRAM, 
UNIVERSllY OF NORTH CAROLINA AT CHAPEL HILL 
and 
UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER IN GAINESVILLE 
STATEMENT OF CONFIDENTIALITY 
The identification number allows us to keep track of the questionnaires as they are returned. Any 
information that would permit identification of an individual or a practice organization will be held 
strictly confidential, will be used only for the purposes of this study, and will not be disclosed or 
released to other persons or used for any other purposes. 
Which of the following services does your hospital provide (Circle only Q!lJ]) 
1. Blood Banking Only l 
2. Blood Banking and Therapeutic Pheresis Services Please continue with the survey 
3. Therapeutic Pheresis Services Only 
4. None of the Above ~Please indicate who provide ese services for your hospital. 
If you circled item# 4, do not answer any further survey question. Please return this survey in 
the enclosed self-addressed envelope to ensure that you are removed from our list. 
WE THANK YOU FOR YOUR TIME. 
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A. BACKGROUND AND PROFESSIONAL PRACTICE 
A-1. What is the zip code of your facility? ____ _ 
A-2. Which of the following best describes your practice site? (Choose !lEi) 
I. University Hospital 
2. University Affiliate 
3. Community Hospital 
4. Local Blood Center 
5. Regional Blood Center 
6. Other (Please describe) 
A-3. What is your current position? 
I. Medical Director 
2. Assistant Medical Director 
3. Laboratory Supervisor 
4. Medical Technologist 
5. Other (Please describe) 
A-4. Which of the following describes your professional training? (Circle all that apply) 
a.MT b. SBB c. MD or DO d. PhD e. Other: _____ _ 
A-5. If you are an MD or DO, which of the following best describes your medical training? 
(Circle all that apply) 
a. Hematology/Oncology 
b. Anatomic Pathology Only 
c. Anatomic and Clinical Pathology 
d. Blood Banking/Transfusion Medicine 
e. Other (please describe) __________ _ 
B. FACILITIES AND SICKLE CELL POPULATION 
B-1. How many units of Red Blood Cells (RBCs) did you transfuse at your hospital last year? 
____ units/year 
B-2. Are you a Trauma Center? 
0. No I. Yes, (please indicate what level ______ ___, 
B-3. Which of the following services do you provide at your hospital? (Circle all that apply) 
a. Simple transfusion 
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b. Manual Exchange Transfusion 
c. Automated Exchange Transfusion 
The remaining questions in this survey refer only to patients with known Sickle Cell Disease (SCD), 
including patients with genotypes such as HbSS, HbSC, HbS~thal, etc. 
BA. Please estimate the number of sickle cell patients your service supports each month. 
____ SCD pts /month 
B-5. What percentage of your sickle cell patients are under 21 years of age? 
_____ %? 
B-6. Do you have a Chronic Transfusion Program at you hospital? 
1. Yes 0. No -;)Please skip to section C 
B-7. What types of patients are in your Chronic Transfusion Program? (Circle all that apply) 
a. Sickle Cell Disease 
b. Thalassemia 
c. Other inherited RBC Diseases 
d. Acquired RBC Diseases 
e. Other ___________ (please indicate) 
C. BLOOD BANKING PRACTICES 
C-1. Do you have policies/procedures specific for ... (Please circle YES or NO for each item) 
a. the Blood Bank work-up of sickle cell patients? 0. NO 1. YES 
b. the distribution ofRBCs to sickle cell patients? 0. NO 1. YES 
C-2. Do your practices differ if a sickle cell patient is ... (Please circle YES or NO for each item) 
a. New to your hospital? 0. NO 1. YES 
b. Known to your hospital? 0. NO 1. YES 
C-3. How frequently are sickle cell patients identified prior to transfusion? (Choose Q!!£) 
I. Always 2. Often 3. Sometimes 4. Rarely 5. Never 
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C-4. Do you perform patient RBC phenotyping ... ? (Choose!!!!£) 
1. Before transfusion of blood products 
2. After transfusion of blood products 
3. After development of an antibody 
4. No typical procedure 
5. Not performed 
C-5. Do you provide this phenotyping information to the patient? 
0. No 
1. Yes -7 please describe how ____________________ _ 
C-6. The following is a list ofRBC products that a Blood Bank might provide for a sickle cell 
patient. Please indicate how often each of the following products is provided for a sickle cel1 
patient in your hospital. 
Blood Product Always Sometimes Rarely 
a. Non-leukocyte reduced RBCs 3 2 I 
b. Leukocyte Reduced RBCs 3 2 I 
c. Irradiated RBCs 3 2 I 
d. Washed RBCs 3 2 I 
e. Sickle cell trait negative RBCs 3 2 I 
f. Frozen RBCs 3 2 I 
g. Other: 3 2 I 
C-7. What is the average age of the RBCs your Blood Bank provides to sickle cell patients? 
(Choose one) 
I. 1-5 days 2. 6- 7 days 3. 8-10 days 4. 11-14 days 5. > 14 days 
C-8. Does your Blood Bank routinely provide phenotypically matched RBCs for sickle cell 
patients? (Choose Q!li) 
I. Yes, perform pre-transfusion prophylactic antigen matching. 
2. Yes, perform prophylactic antigen matching after patient makes an antibody. 
3. No, do not perform prophylactic antigen matching 
(i.e. only honor antibodies patient has already made)-->Skip to question C-10. 
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C-9. Please circle the specific antigens that your blood bank prophylactically matches for. 
Blood Groups Specific Antigens 
Rh D c c E e 
Kell K K 
Duffy Fya Fyb 
Kidd Jka Jkb 
MNS M N s s u 
Others: Please list 
C-10. How difficult is it to obtain phenotypically matched blood for SCD patients? 
I. Very Difficult 2. Somewhat difficult 3. Not difficult at all 
C-11. Does cost influence your current practices/policies? 
0. No 
1. Yes -7 please describe-------------------------
C-12. If cost were not an issue, would you alter your current practices/policies? 
0. No 
l. Yes~ please describe-------------------------
E. TRANSFUSION PRACTICES: CLINICAL MANAGEMENT 
This section of the survey is to be completed by the medical director. 
If you are a laboratory supervisor, please skip ahead to Section F on the next page. 
The following vignettes represent some clinical scenarios that might arise in managing sickle cell patients. 
These are not test items. We are simply interested in describing the different ways sickle cell patients are 
managed at different facilities. We recognize that in rea/life, you might obtain additional information 
prior to making a decision. However, please choose the single best response based on 1) the information 
provided and, 2) how you would manage the patient in your own hospital. 
D-1. A 16 y.o. with sickle cell anemia is scheduled for laparoscopic cholecystectomy. The baseline CBC 
reveals Hct 22% and the Hgb electrophoresis reveals 95% Hb S, 2% Hb A2, and 3% Hb F. 
You recommend the following ... (Circle one) 
1. Perform an exchange transfusion to reduce the Hb S fraction to 30%. 
2. Transfuse RBCs to a Hct of 30%. 
3. Transfuse RBCs to a Hct of36%. 
4. No transfusion is indicated. 
Page 5 o£8 
f 
I 
APPENDIX B-1: Final Survey Instrument 
D-2. A 7 y.o. girl with known sickle cell anemia (Hb SS disease) presents to the Emergency Department 
with a 12-hour history of abdominal pain, nausea, vomiting and lethargy. Physical examination 
reveals an easily palpable and tender spleen. The CBC shows a WBC count of 29,000/uL with 80% 
neutrophils and 12% bands, Hct 12%, PLT- 88,000/uL. The physician in charge requests assistance 
in transfusion recommendations. 
You recommend the following ... (Circle one) 
1. Simple transfusion of packed RBCs 
2. Perform an automated exchange transfusion 
3. Perform a manual exchange transfusion 
4. Transfusion is not indicated 
D-3. A 28 y.o. woman with Hb SC disease has acute chest syndrome with progressive hypoxemia. The 
ICU physician caring has requested transfusion ofRBCs for the patient. Review of the CBC reveals 
WBC 22,000, Hct 28%, platelet count 530,000. 
You recommend the following ... (Circle one) 
I. Simple transfusion of3 U PRCs 
2. Exchange transfusion with target Hct 36% 
3. Exchange transfusion with target Hct 28% 
4. No transfusion is indicated 
D-4. Eight days ago a 29 y.o. African American man with sickle cell anemia (Hb SS) was transfused two 
(2) units of RBCs for treatment of hypoxia. He was discharged from the hospital4 days ago and now 
returns complaining of severe pain of his arms, legs, and back. On physical exam his sclerae are 
icteric and his abdomen is mildly tender in all quadrants. His Hct upon discharge was 26% and now 
it is 14%. He was previously known to have anti-C and anti-K antibodies and on this evaluation there 
is a newly identified anti-S antibody. 
You recommend the following ... (Circle one) 
Transfuse 2 units of compatible RBCs 
Perfonn therapeutic plasmapheresis 
I. 
2. 
3. 
4. 
Perfonn an exchange transfusion with compatible RBCs 
Supportive care and avoid RBC transfusion 
SECTION F: Information and Resources 
Circle the number on the right which best describes Strongly Agree 
how much you agree or disagree with each statement. Agree 
There is clear consensus on .. 
F-4. ... the selection of blood products for sickle 1 2 
cell patients. 
F-5. ... indications for transfusion therapy for 1 2 
sickle cell patients . 
F-6. ... phenotypic matching of blood products 1 2 
for sickle cell patients . 
F-7. . . . the use of chronic transfusion (i.e. 1 2 
hypertransfusion) programs for Sickle 
Cell patients. 
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APPENDIX B-1: Final Survey Instrument 
Circle the number on the right which best describes Strongly Agree Disagree Strongly 
how much you agree or disagree with each Agree Disagree 
statement. 
E-1. My training has prepared me to manage 1 2 3 4 
the transfusion needs sickle cell patients. 
E-2. Information about the blood 1 2 3 4 
bank/transfusion management of sickle cell 
patients is readily available. 
E-3. I am familiar with the National Institutes 1 2 3 4 
of Health Management and Therapy of 
Sickle Cell Disease publication 
E-8. In the past year, I have attended at least one conference on the management of sickle cell 
patients. 
0. No 1. Yes 
E-9. How do you obtain current information on the management of sickle cell patients? 
E-1 0 We are very interested in learning more about your chronic tranfusion program. 
Would you be willing to share your chronic transfusion protocol with us? 
1. Yes, a copy of our protocol is enclosed. 
2. Yes, I will send a copy. 
3. No. 
4. Does not apply, we do not have a chronic transfusion program. 
E-11. Is there anything else about your care of sickle cell patients that you would like to share? 
THIS IS THE END OF THE SURVEY. THANK YOU FOR YOUR TIME! 
To thank you for your participating in this survey, we will send you a brief summary of the survey 
results. If you are interested in receiving a summary, please check the following: 
Yes, I would hke to receive a summary of the survey results. 
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Please return this survey in the enclosed, prepaid envelope and mail to: 
Araba Afenyi-Annan, :MD 
Robert Wood Johnson Clinical Scholars Program 
University of North Carolina at Chapel Hill 
5034 Old Clinic Building, CB# 7105 
Chapel Hill, NC 27599-7105 
Phone: (919) 966-3798 Fax: (919) 843-9237 Email: nyaniba@med.unc.edu 
© Araba Afenyi-Annan 
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{Date} 
Dear {insert name}, 
Enclosed is a survey questionnaire entitled, "The Blood Bank and Transfusion Medicine Management of 
Sickle Cell Disease Patients." We invite you to participate in this research sponsored by The Robert Wood 
Johnson Foundation-Clinical Scholars Program at the University of North Carolina, Chapel Hill, conducted 
jointly with the researchers in the Division of Hematology/Oncology at the University of Florida, and Cecil 
G. Sheps Center for Health Services Research, University of North Carolina. 
The purpose of this study is to gather information on practices, procedures and policies, knowledge, and 
approach to care in the transfusion support of sickle cell disease patients. This survey is being sent to all 
hospital-based blood bank medical directors and laboratory supervisors in North Carolina and Florida 
(estimated sample size of600), in an effort to characterize statewide practices and opportunities to improve 
uniformity of care to this patient population. This survey will take no more than twenty (20) minutes to 
complete. Your response is important to us, as this will ensure that our data is representative of current 
practices. 
Participation in this study is completely voluntary. By completing and returning the survey, you are providing 
your inform consent and agree to participate in this study. Your responses will be kept strictly confidential. 
Any information that would allow identification of an individual or a practice organization will used solely 
for the purposes of this study, will not be disclosed or released to other persons, or used for any other 
purposes. All identifying information will be stored in a locked, secure file and will be destroyed at the 
conclusion of the study (September 1, 2004). Only individuals involved with the study will have access to 
the collected data. 
If you have any questions or comments about this study, please do not hesitate to contact the principle 
investigator, Dr. Araba Afenyi-Annan by email (nyaniba@med.unc.edu) or by telephone at (919) 966-3798. 
An addressed, stamped return envelope is enclosed for your convenience. In addition, we would be pleased 
to provide you a brief summary of the study findings as a thank you for your participation. Please be sure to 
check the corresponding box on the last page of the survey. 
We recognize that there are many demands on your time but hope you will make the effort to contribute to 
the care of sickle cell disease patients in your state. We appreciate your time and participation. 
Sincerely, 
Araba Afenyi-Annan, MD 
University of North Carolina 
RWJ-CSP/Pathology and 
Laboratory Medicine 
Richard Lottenberg, MD 
University of Florida 
Medicine, Division of 
Hematology/Oncology 
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APPENDIX B-2: Cover Letters 
{Date} 
Dear {insert name}, 
Two weeks ago we mailed you a survey seeking information about your blood bank/transfusion medicine 
support to sickle cell disease patients. If you have already completed and returned this survey to us, we thank 
you. If you have not had an opportunity to complete and return the survey, please do so today. We are 
seeking to fully represent the current practices of hospital blood banks in the state of {insert state}. Your 
response is essential to us in 1) describing the current delivery of transfusion support for sickle cell patients 
and 2) guiding efforts to improve the coordination of care for this patient population. Only you can provide 
this information that will be used to improve the quality of care sickle cell patients receive. 
If by chance you have not received the survey, or need another copy, please contact us by phone at (919) 966-
3798 or by email (nyaniba@med.unc.edu). We will be pleased to mail you another copy ofthe survey today. 
A self-addressed, stamped return envelope will also be enclosed for your convenience. If you also check the 
appropriate box on the last page of the survey, we will be pleased to send you a brief summary of the study 
findings as a thank you for your participation in this study. 
We want to remind you that any data you provide to us will be will only be used for the purposes of this 
study and not released to other persons or used for any other purposes. We will make every effort to protect 
your confidentiality. Only individuals involved with this study are authorized to review collected data. If 
you have questions or comments about this study, please contact the principle investigator, Dr. Araba Afenyi-
Annan, at the above number or email address. 
We appreciate your time and hope we may count on your participation. 
Sincerely, 
Araba Afenyi-Annan, MD 
University ofNorth Carolina 
RWJ-CSP/Pathology and 
Laboratory Medicine 
Richard Lottenberg, MD 
University of Florida 
Medicine, Division of 
Hematology/Oncology 
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APPENDIX B-2: Cover Letters 
{Date} 
Dear {insert name}, 
About a month ago, we wrote to you seeking infonnation about your blood bank/transfusion medicine 
support to sickle cell disease patients. As of today, we have not yet received your completed questionnaire. 
You may have sent it back to us already. If so, we thank you. 
If not, another copy is enclosed for your convenience. 
As you know, hospital blood banks play a critical role in managing the care of sickle cell disease patients. 
Our group has undertaken this study because we believe that this role has not been adequately explored. By 
characterizing the current practices of hospital blood banks, we hope to identify opportunities for intervention 
that will improve the quality of care sickle cell patients receive. We know your time is valuable, but please 
help us obtain this information by taking time to answer the enclosed questionnaire. We want to assure that 
we accurately represent all of blood banks in {insert state), especially busy services like yours. 
You can make an important contribution to the management of sickle cell patients by returning the enclosed 
questionnaire today. An addressed stamped envelope is provided for your convenience. We would be happy 
to provide you a brief summary ofthe study findings. Please be sure to indicate on the survey that you would 
like to receive this summary. Your identity will be kept strictly confidential and the information you provide 
will be used only for the purposes of this study, will not be disclosed or released to other persons, or used for 
any other purposes. Questions and comments about this study should be directed to the principle 
investigator, Dr, Araba Afenyi-Annan, at (919) 966-3798 or (nyaniba@med.unc.edu). 
Thank you. We appreciate your time and participation. 
Sincerely, 
Araba Afenyi-Annan, MD 
University ofNorth Carolina 
RWJ-CSP/Pathology and 
Laboratory Medicine 
Richard Lottenberg, MD 
University of Florida 
Medicine, Division of 
Hematology/Oncology 
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APPENDIX B-3: Administration and Coding Procedures 
RWJ SCD SURVEY INSTRUCTIONS 
When Sending Surveys: 
• Addresses will be entered into an Excel database. 
• A mail merge will be performed to enter addresses into letters and addresses labels. 
• Packets will be compiled that contain an introductory letter, a survey and a return envelope. 
• All surveys to a state will be sent at the same time, i.e. all Florida surveys will be sent on one day and all 
North Carolina surveys will be sent on one day. 
When Surveys are Returned: 
• They are logged in using a "l=returned" method in Excel, under the first mailing column. 
• After the determined time period, a postcard reminder is sent. 
• Surveys returned at this point are still considered part of the first mailing and are logged in as such. 
• After the determined time period, a second survey is sent. 
• Surveys returned at this point are considered part of the second mailing and are logged in under that 
category. 
• After the determined time period, a third survey is sent. 
• Surveys returned at this point are considered part of the third mailing and are logged in under that 
category. 
Process for Returned Surveys 
• Date stamp or hand-write date on surveys when they arrive (bottom right-hand corner). 
• Enter into the survey tracking system ("J drive: Tomcat/Araba!Sickle Cell/Tracking???"). Create a 
back-up file on disk and copy to the backup tracking system (as "AAA/rwj/SCD survey /backup of 
tracking system") at least once every two weeks. 
• Once entered, each survey should be reviewed for completeness and accuracy. All tracking and initial 
review ofthe surveys will be performed by the RWJ Research Coordinator. Any missing information, 
incorrect responses (i.e. two items circled or marked, range provided instead of specific number, etc.) 
should be flagged with a yellow highlighter. Any notes or comments for investigator review should be 
marked in red pencil to the left of the questionnaire item {margin). 
• All surveys with problems should be entered into a separate log, ("J drive:Tomcat/Araba!Sickle 
cell/problemlist") listing the ID number, specific issues, etc. prior to coding. 
Process for Coding 
• Prior to data entry, all surveys must be manually coded. 
• All coding will be performed in blue pencil. 
• All forms will be coded by the Research Assistant (or other assigned person), and checked by the 
Research Assistant or principle investigator. As each person tracks, codes and reviews each survey, 
her/his initials and job function (Tracker, Coder, 1st Reviewer, Final Reviewer) will be noted in the 
bottom left-hand corner of the front page of the survey. 
• For open-ended questions, enter word for word responses in Excel file called 
"J:\Tomcat/Araba/Sickle Cell/data/openended" on server. Every survey needs to have open-
ended responses entered before going to data entry. 
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• When coding open-ended responses, ifthere are any other marginal comments (i.e. hand-written), please 
record these in the last field in the open-ended response file under "all other marginal comments", by 
noting the question number and the comment word for word. 
• Newly created variable items (i.e. A2text) are indicated in BOLD. 
• Many questions DO NOT need additional coding. Specific instructions are noted below when an item 
requires coding. All other items not specifically mentioned below must to be checked for accuracy 
and legibility, but no special coding is necessary. Also check all questions for questions omitted by 
respondent, two items circled in one question, etc. 
• Missing data is always coded as 'X'. 
• If don't know is written in, code as 'D', unless otherwise instructed. 
• If not applicable or NA is written in, code as 'N', unless otherwise instructed. 
• Percentages should NOT be rounded. 
DECISION RULES 
• Anytime respondent provides a range (e.g. if they answer question saying 27-33%) code the midpoint of 
the range. 
• If a respondent circles or indicates two responses, or makes a note in between 2 responses (indicating 
they fall between two responses on a continuum), flip a coin to decide (i.e. heads is even number, tails is 
odd number); then code that choice in the margin. 
• Any remaining questions or concerns should be flagged for the principle investigator. 
CODING QUESTION BY QUESTION: 
Screening Question: Code X for missing. If anything else comes up, flag for Araba. 
Screeningtext: 
AI. 
A2. 
If"4" selected, make sure next field (screeningtext) is coded "1" and response 
entered into Excel File word for word. 
Enter 1 if text. 
Enter 0 if no text. 
Enter response word for word into separate Excel file. 
Code X for missing. 
Enter 5-digit zip code. Code X for missing. If anything else comes up, flag for Araba. 
Enter "1-6" (choose one). 
Code X for missing. If anything else comes up, flag for Araba. 
If"6" selected, make sure next field (A2text) is coded as "1") 
A2text. Enter 1 if text. 
A3. 
A4a-e. 
Enter 0 if no text. 
If text, enter word for word into separate excel file. 
Enter "1-5" (choose one). 
If"5" selected, make sure next field (A3text) is coded as "1". 
Code X for missing. 
For each letter, enter "I" for each item selected (all that apply). 
Enter "0" for each item not selected. 
If"e" selected, make sure next field (A4text) is coded "1". 
Code X for missing. 
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A4text. Enter 1 if text. 
A5a-e. 
Enter 0 if no text. 
If text, enter word for word into separate Excel file. 
For each letter, enter "1" for each item selected (all that apply). 
Enter "0" for each item not selected. 
If "e" selected, make sure next field (A5text) is coded "I". 
Code X for missing. 
AStext. Enter 1 if text. 
Bl. 
B2. 
Enter 0 if no text. 
If text, enter word for word into separate Excel file. 
Enter number. If range provided, use midpoint. 
If the symbols"<" or">" are given, enter number indicated after symbol. 
Code X for missing. 
Enter "0" or "1 ", 
If "I" selected, make sure next field (B2text)) is coded "1 ". 
B2text. Enter 1 if text. 
B3a-c. 
B4. 
B5. 
B6. 
B7a-e. 
Enter 0 if no text. 
If text, enter word for word into separate excel file. 
Enter "1" for each letter selected. 
Enter "0" for each letter not selected. 
Code each item as X if no items are checked to indicate that the question was skipped. 
If respondent provides range, code the midpoint of the range. 
If respondent provides range, code the midpoint of the range. 
Enter "0" or "1 ". 
Code X for missing (i.e. no answer indicated). 
Enter "1" for each letter selected. 
Enter "0" for each letter not selected. 
If "e" selected, make sure next item (B7text) is coded "1 ". 
B7text. Enter 1 if text. 
Enter 0 if no text. 
If text, enter word for word into separate Excel file. 
Cia-b. Code each item as X if no items are checked to indicate that the question was skipped. 
C2a-b. Code each item as X if no items are checked to indicate that the question was skipped. 
C3. Code X for missing. 
If response between 2 values, code as odd number (i.e. question #3, odd number). 
C4. Code X for missing. 
C5. Enter "0" or "1 ". 
If"l" selected, make sure next item is coded "1 ". 
C5text. Enter 1 if text. 
Enter 0 if no text. 
If text, enter word for word into separate Excel file. 
C6a-g. Enter "1-4" for each letter. 
If response is between 2 values, code based on above decision rules. 
If"g" selected, make sure next item (C6gtext) is coded "1 ". 
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Code X for missing letter. 
C6gtext. Enter 1 if text. 
Enter 0 if no text. 
If text, enter word for word into separate Excel file. 
C7. Code X for missing. 
If response is between 2 values, code based on above decision rules. 
C-8. Code X for missing. 
If"3" selected, make sure all C-9 items are each coded as X. 
C-9. Code each blood group sequentially as 1 through 6 (Rh=1 --> Others=6). 
C-10. 
C-11. 
C-lltext. 
C-12. 
Code each specific antigen as "a" through "e" (as needed). 
If additional antigens are written in on any row, please flag for Arab a. 
C-9 1 For each letter, enter "I" for each item selected ("a through e"). 
Enter "0" for each item not selected. 
C-9 _ 2 For each letter, enter "1" for each item selected ("a through b"). 
C-9 3 
C-9 4 
C-9 5 
C-9_6 
Enter "0" for each item not selected. 
Please correct colunm "b" to "little k" if not already marked as such. 
For each letter, enter "1" for each item selected ("a through b"). 
Enter "0" for each item not selected. 
For each letter, enter "I" for each item selected ("a through b"). 
Enter "0" for each item not selected. 
For each letter, enter "1" for each item selected ("a through e"). 
Enter "0" for each item not selected. 
If selected, code as "1 ". 
If not selected, code as "0". 
C-9_6text Enter response word for word into Excel file. 
Code X for missing. 
If between 2 responses, code based on above decision rules. 
If"l" selected, make sure next item (C-11 text) is completed. 
Enter response word for word into Excel file. 
If"l" selected, make sure next item is completed. 
Code X for missing. 
SECTION D. If respondent is Laboratory Supervisor, code D-1 through D-4 asS. 
D-1. Code X for missing. 
If response between 2 values, code based on decision rules. 
Please enter any comments or notes into "all marginal comments" file. 
D-2. Code X for missing. 
If response between 2 values, code based on decision rules. 
Please enter any comments or notes into "all marginal comments" file. 
D-3. Code X for missing. 
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D-4. 
SECTION E: 
E-1. 
E-2. 
E-3. 
E-4. 
E-5. 
E-6. 
E-7. 
E-8. 
E-9. 
E-9text. 
E-10. 
E-11. 
E-lltext. 
If response between 2 values, code based on decision rules. 
Please enter any comments or notes into "all marginal comments" file. 
Code X for missing. 
If response between 2 values, code based on decision rules. 
Please enter any comments or notes into "all marginal comments" file. 
PLEASE VERIFY THAT ITEMS E-1 THROUGH E-8 ARE NUMBERED AND 
CODED SEQUENTIALLY (ACCURATELY). MAKE ANY NEEDED 
CORRECTIONS TO THE LEFT OF EACH ITEM. 
Code X for missing. 
If response between 2 values, code based on decision rules. 
Please enter any comments or notes into "all marginal comments" file. 
Code X for missing. 
If response between 2 values, code based on decision rules. 
Please enter any comments or notes into "all marginal comments" file. 
Code X for missing. 
If response between 2 values, code based on decision rules. 
Please enter any comments or notes into "all marginal comments" file. 
Code X for missing. 
If response between 2 values, code based on decision rules. 
Please enter any comments or notes into "all marginal comments" file. 
Code X for missing. 
If response between 2 values, code based on decision rules. 
Please enter any comments or notes into "all marginal comments" file. 
Code X for missing. 
If response between 2 values, code based on decision rules. 
Please enter any comments or notes into "all marginal comments" file. 
Code X for missing. 
If response between 2 values, code based on decision rules. 
Please enter any comments or notes into "all marginal comments" file. 
Code X for missing. 
If text, code as "I '. 
If no text, code as "0". 
Enter text word for word. 
Code X for missing. 
If"l" selected, verify protocol was enclosed with survey. If protocol was not sent with 
the survey, please flag for follow-up as "not sent" in red pencil. 
If"2" selected, verify protocol was enclosed with survey. If protocol was never sent 
please flag for follow-up as "never sent" in red pencil. 
If text, code as "1 ". If"1" selected, please make sure next item (E-lltext) is completed. 
If no text, code as "0". 
Enter response word for word. 
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Request for Summary: Please track summary requests with survey tracking form. Also, create 
a new file "J: Tomcat/ Araba/SCD/summaryrequest" with the following 
information: ID Number, Name, Address, Summary request. 
Enter "1" into Summary request field if item checked off by respondent. Enter 
"0" if not indicated. 
Indicate request entered into tracking system and new file by circling item in 
red pencil. 
Other decisions to be made by Project Manager only (after discussion with PI) ... 
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